No Data
The Market Doesn't Like What It Sees From The United Laboratories International Holdings Limited's (HKG:3933) Earnings Yet
UNITED LAB (03933.HK): The UBT251 injection for chronic kidney disease has received implied clinical trial approval.
On January 22, Gelonghui reported that UNITED LAB (03933.HK) announced that on January 20, 2025, its wholly-owned subsidiary UNITED BIOTECH (Zhuhai Hengqin) Co., Ltd. obtained the clinical trial implied permission from the National Medical Products Administration of China for the phase II clinical trial registration application of the Innovative Drug UBT251 injection for the indication of chronic kidney disease, with acceptance number CXHL2401227. UBT251 is a long-acting GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic peptide)/GCG (glucagon) triple-target compound.
Express News | United Laboratories International - Approval for Clinical Trial of Ubt251 Injection on Indication of Chronic Kidney Disease by Nmpa
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
WuXi AppTec leads the surge of Hong Kong stock pharmaceutical shares, while Global Biomedical investment and financing shows signs of recovery.
① The WuXi AppTec system leads the rise of Hong Kong pharmaceutical stocks, which Bullish factors are worth paying attention to? ② Global Biomedical investment and financing has seen some recovery, how do Institutions view it?
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
